Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail

• DOI: 10.1002/ccr3.4811
• Publication Date: 2021-09-18T07:27:36Z
• Authors: Louisa van den Boom; Theresa Stuecher; Julia K. Mader
• Keywords: Dulaglutide; Girl

Abstract This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.